Metraipolis › archive › dc_bcda7fca8b0a

Evaluation of consistency in adverse event reporting between trial registry and publications in COVID-19 pharmacological intervention trials — Europe PMC PMID:41973364

Source
Europe PMC (en)
Original
https://europepmc.org/article/MED/41973364
DOI
10.1007/s11096-[numero omesso]-2
License (as archived)
solo-consultazione
Archived
2026-10-08T10:00:00.118Z
SHA-256 of the archived text
9a6406be6fa11786edee8fbcbf1107963ac986228fd41e7c2090c32c205eda69
Stable URL of this page
https://metraipolis.com/documento/dc_bcda7fca8b0a

How to cite

Evaluation of consistency in adverse event reporting between trial registry and publications in COVID-19 pharmacological intervention trials — Europe PMC PMID:41973364 — Europe PMC (en), https://europepmc.org/article/MED/41973364 (solo-consultazione); archived copy: https://metraipolis.com/documento/dc_bcda7fca8b0a (Metraipolis archive dc_bcda7fca8b0a, sha256 9a6406be6fa11786edee8fbcbf1107963ac986228fd41e7c2090c32c205eda69)
BibTeX
@misc{dcbcda7fca8b0a,
  title = {Evaluation of consistency in adverse event reporting between trial registry and publications in COVID-19 pharmacological intervention trials — Europe PMC PMID:41973364},
  howpublished = {Europe PMC (en)},
  url = {https://europepmc.org/article/MED/41973364},
  note = {License solo-consultazione; archived copy https://metraipolis.com/documento/dc_bcda7fca8b0a; sha256 9a6406be6fa11786edee8fbcbf1107963ac986228fd41e7c2090c32c205eda69},
  year = {2026}
}

Archived text

The text is not reproduced here: the archive holds it as solo-consultazione (consultation only, no republication). Read it at the original source: https://europepmc.org/article/MED/41973364. Agents can read the archived copy with the MCP tool read_document.